Stephen J Schuster MD

Hematologic Oncology

Professor of Medicine, University of Pennsylvania

3400 Civic Center BlvdPerelman Center for Advanced Medicine, 12th FloorPhiladelphia, PA 19104
Phone+1 215-662-3914

Dr. Schuster is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schuster's full profile Already have an account?

Summary

Dr. Stephen Schuster is a hematologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 36 years. He specializes in hematologic oncology and is experienced in hematologic oncology and leukemia. He has more than 100 publications and over 500 citings.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1988 - 1988
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1984 - 1988
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1981 - 1984
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1981

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2024 - Present
PA State Medical License 1982 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017

Clinical Trials

Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma
UNKNOWN
PHASE3
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
COMPLETED
PHASE1
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
COMPLETED
PHASE2

Publications & Presentations

PubMed

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.
Luca Paruzzo, Emeline R Chong, Elise A Chong, Zhixuan Zheng, Puneeth Guruprasad
Nature Medicine. 2026-08-10
Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden.
Colin J Thomas, Caroline S Myers, Jina Chung, Daniel Landsburg, Sunita D Nasta
Blood Neoplasia. 2026-08-01
FGFR2 is an oncogenic driver critical for successful human gammaherpesvirus latent infection and oncogenesis.
Nian Ma, Dipayan Bose, Jakob Svoboda, Elise A Chong, Stephen J Schuster
Proceedings of the National Academy of Sciences of the United States of America. 2026-07-28

Journal Articles

LRPAP1 Is a Frequent Proliferation-Inducing Antigen of BCRs of Mantle Cell Lymphomas and Can Be Used for Specific Therapeutic Targeting
Stephen J Schuster, Mariusz Wasik, Nature
Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States
Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma
Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Blood

Abstracts/Posters

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-cell TherapyDecember 2022

Press Mentions

Penn Medicine at the 2025 ASH Annual MeetingDecember 2nd, 2025
Around the Nation: FDA Grants Expanded Approval for CAR-T TherapyJune 2nd, 2022
$FDA Approves Novartis Kymriah® CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular Lymphoma$
FDA Approves Novartis Kymriah® CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular LymphomaMay 28th, 2022